Led by Dr. Pankaj K. Singh, the Metabolism Core focuses on studying innovative mechanisms of metabolic and signaling changes that contribute to therapy resistance in pancreatic ductal adenocarcinoma (PDAC).
Integrated into all three projects, the core will provide cost-effective metabolomics services, centralized infrastructure, and expertise. The core will support steady-state polar metabolomics and lipidomics (Specific Aim 1), Stable Isotope Resolved Metabolomics (SIRM) with kinetic flux analysis (Specific Aim 2), and Seahorse extracellular flux analyzer-based assays, fluorescent assays to investigate the metabolic state of cells, and identifying metabolic vulnerabilities (Specific Aim 3). It will conduct these studies on cell lines, organoids, exosomes, and tumor tissues, and offer training and support for drug concentration measurements, metabolism, and pharmacokinetics/pharmacodynamics studies.
